Acquired idiopathic pure red cell aplasia in a hemodialyzed patient with inactive systemic lupus erythematosus. 1994

H Okada, and H Suzuki, and H Uchida, and Y Kanno, and Y Kitamura, and T Hisamatsu, and N Deguchi, and D Hayashi, and T Saruta
Department of Internal Medicine, Keio University School of Medicine, Tokyo.

A male patient suffered chronic renal failure due to lupus nephritis and was undergoing hemodialysis. Six years after beginning hemodialysis, anemia developed, which improved by erythropoietin. Unresponsiveness to erythropoietin gradually appeared, and with a suspicion of pure red cell aplasia, he was treated with a high-dose corticosteroid but the unresponsiveness did not improve. Neither his serum nor lymphocytes inhibited erythropoiesis of either normal bone marrow stem cells or his own in vitro. These observations suggest an impaired hematopoietic microenvironment in his bone marrow.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008181 Lupus Nephritis Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982). Glomerulonephritis, Lupus,Lupus Glomerulonephritis,Nephritis, Lupus,Glomerulonephritides, Lupus,Lupus Glomerulonephritides,Lupus Nephritides,Nephritides, Lupus
D008297 Male Males
D012010 Red-Cell Aplasia, Pure Suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production. Aplasia Pure Red Cell,Erythrocyte Aplasia,Pure Red-Cell Aplasia,Aplasia, Erythrocyte,Aplasia, Pure Red-Cell,Aplasias, Erythrocyte,Erythrocyte Aplasias,Pure Red Cell Aplasia,Pure Red-Cell Aplasias,Red Cell Aplasia, Pure,Red-Cell Aplasias, Pure
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003114 Colony-Forming Units Assay A cytologic technique for measuring the functional capacity of stem cells by assaying their activity. Clonogenic Cell Assay,Stem Cell Assay,Clonogenic Cell Assays,Colony Forming Units Assays,Colony-Forming Units Assays,Stem Cell Assays,Assay, Clonogenic Cell,Assay, Colony-Forming Units,Assay, Stem Cell,Assays, Clonogenic Cell,Assays, Colony-Forming Units,Assays, Stem Cell,Colony Forming Units Assay
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004920 Erythropoiesis The production of red blood cells (ERYTHROCYTES). In humans, erythrocytes are produced by the YOLK SAC in the first trimester; by the liver in the second trimester; by the BONE MARROW in the third trimester and after birth. In normal individuals, the erythrocyte count in the peripheral blood remains relatively constant implying a balance between the rate of erythrocyte production and rate of destruction. Erythropoieses
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses

Related Publications

H Okada, and H Suzuki, and H Uchida, and Y Kanno, and Y Kitamura, and T Hisamatsu, and N Deguchi, and D Hayashi, and T Saruta
October 2003, International journal of urology : official journal of the Japanese Urological Association,
H Okada, and H Suzuki, and H Uchida, and Y Kanno, and Y Kitamura, and T Hisamatsu, and N Deguchi, and D Hayashi, and T Saruta
June 1988, The Journal of rheumatology,
H Okada, and H Suzuki, and H Uchida, and Y Kanno, and Y Kitamura, and T Hisamatsu, and N Deguchi, and D Hayashi, and T Saruta
December 1988, Clinical rheumatology,
H Okada, and H Suzuki, and H Uchida, and Y Kanno, and Y Kitamura, and T Hisamatsu, and N Deguchi, and D Hayashi, and T Saruta
February 1996, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases,
H Okada, and H Suzuki, and H Uchida, and Y Kanno, and Y Kitamura, and T Hisamatsu, and N Deguchi, and D Hayashi, and T Saruta
June 1992, Anales de medicina interna (Madrid, Spain : 1984),
H Okada, and H Suzuki, and H Uchida, and Y Kanno, and Y Kitamura, and T Hisamatsu, and N Deguchi, and D Hayashi, and T Saruta
January 2014, Acta reumatologica portuguesa,
H Okada, and H Suzuki, and H Uchida, and Y Kanno, and Y Kitamura, and T Hisamatsu, and N Deguchi, and D Hayashi, and T Saruta
January 1995, Scandinavian journal of rheumatology,
H Okada, and H Suzuki, and H Uchida, and Y Kanno, and Y Kitamura, and T Hisamatsu, and N Deguchi, and D Hayashi, and T Saruta
October 1993, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed,
H Okada, and H Suzuki, and H Uchida, and Y Kanno, and Y Kitamura, and T Hisamatsu, and N Deguchi, and D Hayashi, and T Saruta
September 1985, Arthritis and rheumatism,
H Okada, and H Suzuki, and H Uchida, and Y Kanno, and Y Kitamura, and T Hisamatsu, and N Deguchi, and D Hayashi, and T Saruta
June 2006, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology,
Copied contents to your clipboard!